Anti-Natalizumab ELISA Assay Kit


The Anti-Natalizumab ELISA Assay Kit is intended as an analytical tool for quantitative determination of Anti-Natalizumab in serum, plasma, and cell culture supernatant.

SKU: KBI2020 Categories: , , Tag:

Anti-Natalizumab ELISA Assay Kit

The Anti-Natalizumab ELISA Assay Kit is For Research Use Only

Size: 12×8 wells
Sensitivity: < 10 ng/mL
Standard Range: 10-640 ng/ml
Incubation Time: 2.25 houurs
Sample Type: Serum, Plasma, Cell Culture Supernatants
Sample Size: 100 µl
Alternative Name: Tysabri

Assay Background

Natalizumab is a humanized monoclonal antibody against the cell adhesion molecule α4-integrin. Natalizumab is used in the treatment of multiple sclerosis and Crohn’s disease. It is co-marketed by Biogen and Élan as Tysabri, and was previously named Antegren. Natalizumab is administered by intravenous infusion every 28 days. The drug is believed to work by reducing the ability of inflammatory immune cells to attach to and pass through the cell layers lining the intestines and blood–brain barrier. Natalizumab has proven effective in treating the symptoms of both diseases, preventing relapse, vision loss, cognitive decline and significantly improving quality of life in people with multiple sclerosis, as well as increasing rates of remission and preventing relapse in Crohn’s disease. Anti-Drug Antibodies (ADA) may induce unwanted side effects in biopharmaceuticals. Hence, ADA has been subjected to increase in scrutiny by the regulatory authorities using immunogenicity safety studies. ADA has been observed in pre-clinical and clinical studies, resulting in significant changes in toxicology, pharmacokinetics and efficacy. These effects result from the generation of drug-induced (neutralizing) autoantibodies against Natalizumab and can be responsible for allergic reaction, or even anaphylactic shock. This ELISA kit detects antibodies for Anti-Natalizumab and may be used for monitoring immunogenicity.

Related Products

Natalizumab ELISA Assay Kit
Anti-Omalizumab (Xolair) ELISA Assay Kit
Anti-Tocilizumab (Actermra) ELISA Assay Kit

Additional Information

Assay Principle

The method employs the quantitative sandwich enzyme immunoassay technique. Natalizumab is pre-coated onto microwells. Samples and standards are pipetted into microwells and antibodies to Natalizumab present in the sample are bound by the capture antibody. Then, a HRP (horseradish peroxidase) conjugated Natalizumab is pipetted and incubated. After washing microwells in order to remove any non- specific binding, the ready to use substrate solution (TMB) is added to microwells and color develops proportionally to the amount of Anti-Natalizumab in the sample. Color development is then stopped by addition of stop solution. Absorbance is measured at 450 nm.

Package Inserts

Please note: All documents above are for reference use only and should not be used in place of the documents included with this physical product. If digital copies are needed, please contact us.

Product Citations